Teicoplanin-containing cement spacers for treatment of experimental Staphylococcus aureus joint prosthesis infection.
Using a rabbit model of methicillin-resistant Staphylococcus aureus knee-prosthesis infection, we studied the efficacy of teicoplanin cement alone or in combination with systemic intramuscular (i.m.) injections of teicoplanin. Seven days after infection, surgical debridement and removal of the infected prostheses were performed, and five rabbits were randomly assigned to one of five different treatment groups: untreated controls, prosthesis replacement by drug-free cement spacer, prosthesis replacement by teicoplanin-loaded cement spacer (1.2 g of teicoplanin/40 g of cement), i.m. injections of teicoplanin (20 mg/kg of body weight, twice a day for 7 days), or systemic antibiotic treatment combined with teicoplanin-loaded spacers. The most effective regimen combined systemic teicoplanin and antibiotic spacers.
D000818:Animals; D001843:Bone Cements; D001842:Bone and Bones / Q000378:metabolism; D004195:Disease Models, Animal; D007273:Injections, Intramuscular; D007595:Joint Prosthesis / Q000382:microbiology*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D016459:Prosthesis-Related Infections / Q000188:drug therapy*; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus; D017334:Teicoplanin / Q000008:administration & dosage*; D016896:Treatment Outcome
D001843:Bone Cements; D017334:Teicoplanin